Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Dia
September 14 2007 - 4:37PM
PR Newswire (US)
SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. (NASDAQ:AMLN) management will be presenting a
corporate overview at an investor reception during the 43rd Annual
Meeting of the European Association for the Study of Diabetes
(EASD) on Wednesday, September 19, 2007 at 4:30 a.m. PT / 1:30 p.m.
CET local time in Amsterdam, Netherlands. The live presentation
will be webcast, and recordings will be made available following
the event. The webcast and recording will be accessible through
Amylin's corporate website, located at http://www.amylin.com/. To
access the live webcasts, please log on to Amylin's site
approximately fifteen minutes prior to the presentation to register
and download any necessary audio software. More information about
the EASD meeting is available at: http://www.easd.org/. About
Amylin Pharmaceuticals Amylin Pharmaceuticals is a
biopharmaceutical company committed to improving lives through the
discovery, development and commercialization of innovative
medicines. Amylin has developed and gained approval for two
first-in-class medicines for diabetes, SYMLIN(R) (pramlintide
acetate) injection and BYETTA(R) (exenatide) injection. Amylin's
research and development activities leverage the company's
expertise in metabolism to develop potential therapies to treat
diabetes and obesity. Amylin is located in San Diego, California
with over 1,800 employees nationwide. Further information on Amylin
Pharmaceuticals is available at http://www.amylin.com/. DATASOURCE:
Amylin Pharmaceuticals, Inc. CONTACT: Alice Bahner Izzo, Executive
Director of Corporate Affairs of Amylin Pharmaceuticals, Inc.,
+1-858-552-2200, ext. 7272 Web site: http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024